Morphine PCA vs Morphine and Lidocaine PCA for the treatment of vaso-occlusive crisis-related pain in sickle-cell anaemia patients: a prospective, randomized, double blind monocentric trial.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Decision date
26/01/2026
Enrollment target
40
Sites
Belgium
Condition studied
sickle cell anaemia
Investigational medicinal product(s)
LIDOCAINE HYDROCHLORIDEMORPHINE HYDROCHLORIDE
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Reduction in morphine consumption
Endpoint detail
Evolution of biomarkers, Evolution of pain scores using the VAS score, Occurence of morphine-related adverse effects
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.